Next Treatments
Back to Eczema

rezpegaldesleukin

Also known as REZPEG

TypeInjection StagePhase 3 Latest updateUpdated recently. Aug 7, 2026Phase 3 study started

What stands out

New approach in eczema

  • A made form of IL-2, a signal that grows T cells, including the regulatory ones that calm immunity
  • Injection every 2, 4 or 12 weeks in trials
Derived from FDA substance registry · NCT07711418 · UniProt P60568 ·
11 US eczema labels (Cibinqo, Eucrisa, Adquey, Dupixent, Ebglyss, Nemluvio, Zoryve, Opzelura, Vtama, Adbry, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Dec 4, 2019. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Aug 7, 2026Phase 3 trial startedA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT07711418
  • Jun 29, 2026Phase 3 trial startedA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT07690371
  • May 6, 2025Phase 2 main data collectedA Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT06136741
  • Nov 15, 2023Phase 2 trial startedA Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT06136741
  • Jun 24, 2022Phase 1 trial completed · Basic-science trialA Study of LY3471851 in Participants With Eczema ClinicalTrials.gov NCT04081350
  • Dec 4, 2019Phase 1 trial started · Basic-science trialA Study of LY3471851 in Participants With Eczema ClinicalTrials.gov NCT04081350

Sources

Trials